We therefore decided to investigate the role of ACBP/DBI in preclinical models of active fatty liver disease, hence administering a neutralizing anti-ACBP/DBI mAb to mice with manifest MASH and/or fibrosis. The gene discussed is DBI; the disease is fatty liver disease.